D-Pharm Ltd. Selects Tigermed for Trial of Stroke Drug

Published: Nov 04, 2010

November 4, 2010 -- D-Pharm of Israel will entrust Hangzhou Tigermed Consulting Co. with a Phase III China clinical trial of its stroke treatment. Tigermed will also be in charge of China regulatory filings for DP-b99, a neuroprotective drug. Wanbang Biopharma, which will market the drug in China for D-Pharm, also signed the contract. More details....

Back to news